MarketPeel
Insider Trading Intelligence
DS

David Shook

NKTX
CHIEF MEDICAL OFFICER · NKARTA, INC. · CIK 0001959742
FILING MIX · LIFETIME60%/40%
BUYS
12
SELLS
8
TOTAL VALUE
$90.0K
COMPANIES
2
ACTIVE SINCE
Jan 2023
HOLDINGS NOW
211,878
AVG SELL PX
$5.02
TRADE KIND
SHOWING 20 / 20
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 1 pending
Forward-return performance of every backtestable P/S trade by David Shook, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+66.67%-5.40%+0.87%-6.26%-4.76%
14d6+50.00%-8.33%+1.88%-10.20%-1.89%
30d6+66.67%-4.15%+2.65%-6.80%-5.76%
60d6+66.67%-10.19%-0.13%-10.05%-14.27%
90d6+50.00%-8.93%+1.75%-10.69%-10.36%
180d6+83.33%+51.05%+12.26%+38.78%-41.46%
1y6+50.00%+17.34%+21.69%-4.36%-24.11%
2y6(1 pending)+80.00%-43.96%+44.93%-88.89%-102.51%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NKTX · 190,955 shares · as of Jan 15, 2025
052,000104,000156,000208,00020242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 12 buys / 8 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
LYEL
LYELL IMMUNOPHARMA, INC.
SALE
Chief Medical Officer
1,977$12.64$25.0K20,923Jun 10, 2026Jun 11, 2026View →
LYEL
LYELL IMMUNOPHARMA, INC.
PURCHASEGRANT
Stock grant
50,00050,000Feb 10, 2026Feb 11, 2026View →
LYEL
LYELL IMMUNOPHARMA, INC.
PURCHASEGRANT
Stock grant
21,90021,900Jun 9, 2025Jun 11, 2025View →
LYEL
LYELL IMMUNOPHARMA, INC.
PURCHASEGRANT
Stock grant
43,75043,750Jun 9, 2025Jun 11, 2025View →
NKTX
NKARTA, INC.
SALE
See Remarks
8,638$2.20$19.0K190,955Jan 15, 2025Jan 17, 2025View →
NKTX
NKARTA, INC.
PURCHASEGRANT
Stock grant
59,000199,593Jan 3, 2025Jan 7, 2025View →
NKTX
NKARTA, INC.
PURCHASEGRANT
Stock grant
117,500117,500Jan 3, 2025Jan 7, 2025View →
NKTX
NKARTA, INC.
SALEGRANT
Stock grant
1,352$5.11$6.9K138,593Aug 21, 2024Aug 23, 2024View →
NKTX
NKARTA, INC.
PURCHASEGRANT
Stock grant
30,00030,000Jul 15, 2024Jul 31, 2024View →
NKTX
NKARTA, INC.
PURCHASEGRANT
Stock grant
23,421139,945Jul 15, 2024Jul 31, 2024View →
NKTX
NKARTA, INC.
SALE
Chief Medical Officer
456$5.60$2.6K116,524Jun 18, 2024Jun 20, 2024View →
NKTX
NKARTA, INC.
SALE
Chief Medical Officer
3,552$8.74$31.0K114,980Jan 16, 2024Jan 18, 2024View →
NKTX
NKARTA, INC.
PURCHASEGRANT
Stock grant
112,500112,500Jan 4, 2024Jan 8, 2024View →
NKTX
NKARTA, INC.
PURCHASEGRANT
Stock grant
56,000118,532Jan 4, 2024Jan 8, 2024View →
NKTX
NKARTA, INC.
SALE
Chief Medical Officer
1,331$1.83$2.4K60,532Aug 21, 2023Aug 23, 2023View →
NKTX
NKARTA, INC.
PURCHASEGRANT
Stock grant
208,000208,000Jul 1, 2023Jul 5, 2023View →
NKTX
NKARTA, INC.
SALE
Chief Medical Officer
439$4.85$2.1K61,863Jun 20, 2023Jun 22, 2023View →
NKTX
NKARTA, INC.
SALE
Chief Medical Officer
175$5.49$96160,302Jan 17, 2023Jan 18, 2023View →
NKTX
NKARTA, INC.
PURCHASEGRANT
Stock grant
75,00075,000Jan 13, 2023Jan 18, 2023View →
NKTX
NKARTA, INC.
PURCHASEGRANT
Stock grant
37,50060,477Jan 13, 2023Jan 18, 2023View →
Other insiders · NKTX
Loading peer insiders…
About this filer
CIK 0001959742
ROLE
Chief Medical Officer
PRIMARY
NKTX
COMPANIES
2
ACTIVE SINCE
Jan 2023
MARKETPEEL · /INSIDER/0001959742DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback